Oxyresveratrol (trans-Oxyresveratrol) 是一种有效的天然抗氧化剂和自由基清除剂 (对 DPPH 自由基的IC50为 28.9 μM)。Oxyresveratrol 是一种有效的非竞争性酪氨酸酶 (tyrosinase) 抑制剂,对蘑菇酪氨酸酶的IC50值为 1.2 μM。Oxyresveratrol 对HSV-1,HSV-2和水痘带状疱疹病毒 (varicella-zoster virus) 有效,并具有神经保护作用。
生物活性 | Oxyresveratrol (trans-Oxyresveratrol) is a potent naturally occurring antioxidant and free radical scavenger (IC50of 28.9 μM against DPPH free radicals). Oxyresveratrol is potent and noncompetitivetyrosinaseinhibitor with anIC50value of 1.2 μM for mushroomtyrosinase. Oxyresveratrol is effective againstHSV-1,HSV-2andvaricella-zoster virus, and has neuroprotective effects[1][2][3][4]. |
IC50& Target | |
体外研究 (In Vitro) | Cultures of the murine microglial cell line N9 and primary mixed glial cultures were used to test the drug effects of NO production upon expression of the inducible isoform of nitric oxide synthase (iNOS). Oxyresveratrol considerably diminished NO (nitrite) levels (IC50of 45.31 μM) in murine microglial cells[1]. Oxyresveratrol can inhibit DOPA oxidase activity, cyclooxygenase, and rat liver mitochondrial ATPase activity[1]. Oxyresveratrol exhibits 63.3% inhibition at 100 μM and an IC50value of 52.7 μM on the murine tyrosinase activity. Oxyresveratrol exhibits a dose-dependent inhibitory effect on L-tyrosine oxidation by the murine tyrosinase but does not inhibit the promoter activity of the enzyme gene. Oxyresveratrol exhibits significant inhibitory effects at 10 μM and higher concentrations on murine tyrosinase activity[2].
|
体内研究 (In Vivo) | Oxyresveratrol (2-30 mg/kg; intraperitoneal injection; twice) treatment reduces the brain infarct volume in MCAO rats. Oxyresveratrol treatment diminishes cytochrome c release and decreased caspase-3 activation, and reduces the number of apoptotic nuclei in ischemic brain in MCAO rats[3].
Animal Model: | Adult male Wistar rats (300-350 g) with middle cerebral artery occlusion (MCAO)[3] | Dosage: | 2 mg/kg, 10 mg/kg, 20 mg/kg and 30 mg/kg | Administration: | Intraperitoneal injection; twice (at the time of occlusion and at the time of reperfusion) | Result: | Reduced the brain infarct volume in MCAO rats. |
|
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | |
来源 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : 50 mg/mL(204.72 mM;Need ultrasonic) 配制储备液 1 mM | 4.0943 mL | 20.4717 mL | 40.9433 mL | 5 mM | 0.8189 mL | 4.0943 mL | 8.1887 mL | 10 mM | 0.4094 mL | 2.0472 mL | 4.0943 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.24 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.24 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (10.24 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|